A recent study found higher levels of TROP-2 in most BC subtypes (except in the neuroendocrine subtype) and revealed that after prolonged Enfortumab Vedotin (EV) exposure, cells can downregulate Nectin-4, leading to EV resistance, but retain TROP-2 expression and remain sensitive to sacituzumab govitecan, suggesting non-overlapping resistance mechanisms to ADCs [31,32]. Here, TACSTD2 is linked to breast cancer.